BACKGROUND: Converging evidence has implicated endogenous neurotensin (NT) in the pathophysiology of brain processes relevant to schizophrenia. Prepulse inhibition of the startle reflex (PPI) is a measure of sensorimotor gating and considered to be of strong relevance to neuropsychiatric disorders associated with psychosis and cognitive dysfunction. Mice genetically engineered to not express NT display deficits in PPI that model the PPI deficits seen in schizophrenia patients. NT1 receptors have been most strongly implicated in mediating the psychosis relevant effects of NT such as attenuating PPI deficits. To investigate the role of NT1 receptors in the regulation of PPI, we measured baseline PPI in wildtype (WT) and NT1 knockout (KO) mice. We also tested the effects of amphetamine and dizocilpine, a dopamine agonist and NMDA antagonist, respectively, that reduce PPI as well as the NT1 selective receptor agonist PD149163, known to increase PPI in rats. METHODS: Baseline PPI and acoustic startle response were measured in WT and NT1 KO mice. After baseline testing, mice were tested again after receiving intraperatoneal (IP) saline or one of three doses of amphetamine (1.0, 3.0 and 10.0 mg/kg), dizocilpine (0.3, 1.0 and 3.0 mg/kg) and PD149163 (0.5, 2.0 and 6.0 mg/kg) on separate test days. RESULTS: Baseline PPI and acoustic startle response in NT1 KO mice were not significantly different from NT1 WT mice. WT and KO mice exhibited similar responses to the PPI-disrupting effects of dizocilpine and amphetamine. PD149163 significantly facilitated PPI (P < 0.004) and decreased the acoustic startle response (P < 0.001) in WT but not NT1 KO mice. CONCLUSIONS: The data does not support the regulation of baseline PPI or the PPI disruptive effects of amphetamine or dizocilpine by endogenous NT acting at the NT1 receptor, although they support the antipsychotic potential of pharmacological activation of NT1 receptors by NT1 agonists.
BACKGROUND: Converging evidence has implicated endogenous neurotensin (NT) in the pathophysiology of brain processes relevant to schizophrenia. Prepulse inhibition of the startle reflex (PPI) is a measure of sensorimotor gating and considered to be of strong relevance to neuropsychiatric disorders associated with psychosis and cognitive dysfunction. Mice genetically engineered to not express NT display deficits in PPI that model the PPI deficits seen in schizophreniapatients. NT1 receptors have been most strongly implicated in mediating the psychosis relevant effects of NT such as attenuating PPI deficits. To investigate the role of NT1 receptors in the regulation of PPI, we measured baseline PPI in wildtype (WT) and NT1 knockout (KO) mice. We also tested the effects of amphetamine and dizocilpine, a dopamine agonist and NMDA antagonist, respectively, that reduce PPI as well as the NT1 selective receptor agonist PD149163, known to increase PPI in rats. METHODS: Baseline PPI and acoustic startle response were measured in WT and NT1 KO mice. After baseline testing, mice were tested again after receiving intraperatoneal (IP) saline or one of three doses of amphetamine (1.0, 3.0 and 10.0 mg/kg), dizocilpine (0.3, 1.0 and 3.0 mg/kg) and PD149163 (0.5, 2.0 and 6.0 mg/kg) on separate test days. RESULTS: Baseline PPI and acoustic startle response in NT1 KO mice were not significantly different from NT1 WT mice. WT and KO mice exhibited similar responses to the PPI-disrupting effects of dizocilpine and amphetamine. PD149163 significantly facilitated PPI (P < 0.004) and decreased the acoustic startle response (P < 0.001) in WT but not NT1 KO mice. CONCLUSIONS: The data does not support the regulation of baseline PPI or the PPI disruptive effects of amphetamine or dizocilpine by endogenous NT acting at the NT1 receptor, although they support the antipsychotic potential of pharmacological activation of NT1 receptors by NT1 agonists.
Authors: E Widerlöv; L H Lindström; G Besev; P J Manberg; C B Nemeroff; G R Breese; J S Kizer; A J Prange Journal: Am J Psychiatry Date: 1982-09 Impact factor: 18.112
Authors: B Olivier; C Leahy; T Mullen; R Paylor; V E Groppi; Z Sarnyai; D Brunner Journal: Psychopharmacology (Berl) Date: 2001-07 Impact factor: 4.530
Authors: Hreinn Stefansson; Engilbert Sigurdsson; Valgerdur Steinthorsdottir; Soley Bjornsdottir; Thordur Sigmundsson; Shyamali Ghosh; Jon Brynjolfsson; Steinunn Gunnarsdottir; Omar Ivarsson; Thomas T Chou; Omar Hjaltason; Birgitta Birgisdottir; Helgi Jonsson; Vala G Gudnadottir; Elsa Gudmundsdottir; Asgeir Bjornsson; Brynjolfur Ingvarsson; Andres Ingason; Sigmundur Sigfusson; Hronn Hardardottir; Richard P Harvey; Donna Lai; Mingdong Zhou; Daniela Brunner; Vincent Mutel; Acuna Gonzalo; Greg Lemke; Jesus Sainz; Gardar Johannesson; Thorkell Andresson; Daniel Gudbjartsson; Andrei Manolescu; Michael L Frigge; Mark E Gurney; Augustine Kong; Jeffrey R Gulcher; Hannes Petursson; Kari Stefansson Journal: Am J Hum Genet Date: 2002-07-23 Impact factor: 11.025
Authors: Chelsea A Vadnie; Jennifer Ayers-Ringler; Alfredo Oliveros; Osama A Abulseoud; Sun Choi; Mario J Hitschfeld; Doo-Sup Choi Journal: Behav Brain Res Date: 2016-02-22 Impact factor: 3.332
Authors: David Feifel; Zhen Pang; Zheng Pang; Paul D Shilling; Gilia Melendez; Rudy Schreiber; Donald Button Journal: Behav Brain Res Date: 2010-04-21 Impact factor: 3.332
Authors: Chelsea A Vadnie; David J Hinton; Sun Choi; YuBin Choi; Christina L Ruby; Alfredo Oliveros; Miguel L Prieto; Jun Hyun Park; Doo-Sup Choi Journal: Neuropharmacology Date: 2014-06-11 Impact factor: 5.250